SCIENTIFIC ADVISORY COUNCIL We look to the best experts to inform our care guidelines for patients and care providers. Our Scientific Advisory Council (SAC) is made up of experts in […]
Osteoporosis Canada together with Canada’s National Ballet School brings you Dance! Ballet for Bone Health. This virtual adult ballet class is a great way to learn the basics of ballet […]
We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
There has been recent media coverage concerning a rare atypical femoral fracture that may be a side effect of denosumab (Prolia), an osteoporosis medication manufactured by Amgen. Osteoporosis Canada’s Scientific […]
Osteoporosis Canada’s overall position statement in response to this study: This study did not specifically address the vitamin D requirements of individuals with osteoporosis, those with risk factors for osteoporotic […]
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
